Novavax Nuvaxovid gets full marketing authorization in EU for COVID prevention

Published On 2023-07-09 04:30 GMT | Update On 2024-02-12 20:34 GMT

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for Nuvaxovid (NVX-CoV2373).

This decision follows positive opinion for a full MA from the Committee for Medicinal Products for Human Use of the European Medicines Agency. The vaccine is now fully authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older for the prevention of COVID-19. Nuvaxovid was originally granted a conditional MA in the EU for these indications.

"This Marketing Authorization establishes the foundation for all future regulatory approvals for updated versions of our COVID vaccine, a necessity to ensure we can quickly get our vaccine to individuals in the EU," said John C. Jacobs, President and Chief Executive Officer, Novavax. "In addition to the EU, we are preparing to file for full approval in the U.S. as well as other markets and are committed to ensuring protein-based options are available worldwide. Vaccine choice remains an integral part of public health measures."

The Phase 3 PREVENT-19 trial demonstrated Nuvaxovid's reassuring safety profile as well as efficacy as a primary series in adults, the immunogenicity and safety as a booster dose in adults, and the efficacy and safety as a primary series in individuals aged 12 and older.

Novavax's COVID vaccine is authorized for use in more than 40 markets around the world.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Novavax Nuvaxovid gets full marketing authorization in EU for COVID prevention

Similar News

Price Cap Exemption Pending: NPPA Refers Biodeal Pharma's Midazolam Nasal Spray to CDSCO, SNCM for Review

Zydus Gets CDSCO Panel Nod for Phase III Trial of Dextromethorphan, Phenylephrine Cough Syrup FDC

Toxic Coldrif Fallout: Tamil Nadu Govt Issues Show-Cause Notice to Sresan Pharma, License at Risk

Maharashtra B.Pharm Admissions 2025: 29,166 Students Allotted Seats in First Round

Zydus Lifesciences gets NOC from Health Canada for hypothyroidism tablets

Zydus Lifesciences secures USFDA okay for Duchenne Muscular Dystrophy drug

Coldrif Syrup banned in Maharashtra after child deaths

Sensitise public on alert against Coldrif cough syrup batch: Telangana govt directs health officials